Supplementary Figure S8 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.